Infusion Reactions in Autoimmune Disease to Rituximab
Research type
Research Study
Full title
Characterising the Pathophysiology of Infusion Reactions to Rituximab in Autoimmune Disease
IRAS ID
211122
Contact name
Maria Leandro
Contact email
Sponsor organisation
University College London
Duration of Study in the UK
3 years, 0 months, 4 days
Research summary
The principal aim of the proposed study is to undertake a detailed analysis of patients with autoimmune disease (e.g. Rheumatoid Arthritis, Systemic Lupus Erythematous etc) who have developed an infusion reaction to Rituximab (an effective biologic medication given via infusion). The underlying mechanism of these reactions has not been characterised in the existing medical literature. We also would like to possibly identify a subgroup that may be at a higher risk of adverse infusion reactions, enabling us to find ways of avoiding such reactions. Increased knowledge of mechanisms can help decide whether re-treatment with a desensitisation protocol is an option for the individual patient.
This study encompasses both a retrospective and a prospective arm.REC name
London - Westminster Research Ethics Committee
REC reference
17/LO/0138
Date of REC Opinion
31 Mar 2017
REC opinion
Further Information Favourable Opinion